NCT05493553 is a NA clinical trial of Dietary supplement regimen in Healthy, sponsored by Unicity International, Inc..

Who is sponsoring NCT05493553?

NCT05493553 is sponsored by Unicity International, Inc..

What drugs are being tested in NCT05493553?

Interventions in NCT05493553: Dietary supplement regimen, Dietary supplement and intermittent fasting regimen.

What condition does NCT05493553 study?

NCT05493553 studies Healthy, Impaired Glucose Tolerance.

Is NCT05493553 still recruiting?

NCT05493553 is currently completed. Last updated 1 November 2022.

Last reviewed 2022-11-01 · How we verify

NCT05493553

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability

Completed NA Last updated 1 November 2022

What this trial tests

NA trial testing Dietary supplement regimen in Healthy in 50 participants. Completed in 29 September 2022.

Timeline

8 August 2022

Primary endpoint
29 September 2022

29 September 2022

Quick facts

Lead sponsor	Unicity International, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	single
Primary purpose	prevention
Enrollment	50
Start date	8 August 2022
Primary completion	29 September 2022
Estimated completion	29 September 2022
Sites	1 location across United States

Drugs / interventions tested

Dietary supplement regimen
Dietary supplement and intermittent fasting regimen

Conditions studied

Healthy — all drugs for Healthy →
Impaired Glucose Tolerance — all drugs for Impaired Glucose Tolerance →

Sponsor

Unicity International, Inc.

Who can join

Adults 30 to 69, any sex, with Healthy or Impaired Glucose Tolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the short-term effect of a nutritional program consisting of a yerba mate supplement, fiber supplement, and intermittent fasting on glycemic variability in men and women with risk factors for impaired fasting glucose.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05493553 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Unicity International, Inc.
Last refreshed: 1 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05493553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing